Status:

RECRUITING

Mechanisms of Semaglutide Therapy in Heart Failure Patients

Lead Sponsor:

University Medical Centre Ljubljana

Collaborating Sponsors:

Stanford University

Greenstone Biosciences

Conditions:

Heart Failure

Obesity

Eligibility:

All Genders

20-80 years

Phase:

PHASE1

PHASE2

Brief Summary

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cell...

Eligibility Criteria

Inclusion

  • Age: 20-80 years
  • Presence of heart failure
  • Body-mass index 27 kg/m2 or greater
  • Stable optimally tolerated dosages of heart failure therapies for 3 months
  • N-terminal pro B-type natriuretic peptide levels \>350 pg/mL

Exclusion

  • Presence of type 1 or type 2 diabetes or glycated haemoglobin higher than 6.5%
  • Pregnancy or potential to become pregnant
  • Cancer
  • Liver dysfunction (aspartate aminotransferase and/or alanine aminotransferase \> 3 times upper limits of normal or total bilirubin greater than 1.5 times upper limits of normal)
  • Renal dysfunction (estimated glomerular filtration rate less than 25 mL/min/1.73 m2)
  • Hospitalization in the past 3 months for reasons other than heart failure
  • New York Heart Association (NYHA) functional class I or functional class IV symptoms.
  • Prior or planned bariatric surgery
  • Self-reported change in body weight \>11 lbs (5 kg) within 3 months before enrollment
  • Acute or chronic infection

Key Trial Info

Start Date :

July 10 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2025

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT06541509

Start Date

July 10 2024

End Date

September 1 2025

Last Update

August 7 2024

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Greenstone Biosciences

Palo Alto, California, United States, 94304

2

Stanford Cardiovascular Institute

Stanford, California, United States, 94305

3

University Medical Center Ljubljana

Ljubljana, Slovenia, 1000

Mechanisms of Semaglutide Therapy in Heart Failure Patients | DecenTrialz